Skip to content

Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation

An Assessment of Patient Outcomes Following a Rehabilitation Programme for Patients Who Have Received Lung or Heart-Lung Transplant - a Randomised Controlled Trial

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00129350
Enrollment
60
Registered
2005-08-11
Start date
2004-09-30
Completion date
2008-02-29
Last updated
2005-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alveolitis, Fibrosing, Bronchiectasis, Cystic Fibrosis, Emphysema, Lung Diseases

Keywords

End Stage Fibrotic Lung Disease

Brief summary

At present, a specific community based rehabilitation programme for lung or heart-lung transplant recipients does not exist. 160 hospitals throughout the United Kingdom (UK) offer pulmonary rehabilitation programmes. The programmes operate under evidence-based guidelines as outlined by the Chartered Society of Physiotherapy. Increasing evidence shows that rehabilitation programmes help improve performance, exercise endurance, and quality of life; and reduce symptoms and demand on health-care resources. This study proposes to compare the outcomes of lung and heart-lung transplant patients attending local pulmonary rehabilitation against others receiving the Trust's current document-based programme. The study is a randomized controlled trial: * Control Arm: Those patients randomized to the 'control' arm will receive the Trust's standard rehabilitation programme that consists of an information pack supplied upon discharge. They will then complete and undertake the following tests: Short-Form 36 (SF 36; version 2) Questionnaire, Chronic Respiratory Questionnaire (CRQ-SR), Incremental Shuttle Walk Test and Spirometry forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC). The patient will follow the information contained in the information pack and the above tests and questionnaires will be repeated 6 months post discharge. * Experimental Arm: A patient who is randomized to the 'experimental' arm will be asked to complete the following tests upon discharge: Short-Form 36 (SF 36; version 2) Questionnaire, Chronic Respiratory Questionnaire (CRQ-SR), Incremental Shuttle Walk Test and Spirometry FEV1 and FVC. Three months post discharge, the patient will be enrolled into a local pulmonary rehabilitation programme. The programme is typically structured to last 6-12 weeks. The above tests and questionnaires will be repeated 6 months post discharge. To measure the effectiveness of either the information pack or the rehabilitation programme the following endpoints will be subjected to analysis in both the experimental and the control group: * Short-Form 36 Questionnaire; * Chronic Respiratory Questionnaire; * Incremental Shuttle Walk Test; * Borg Scale; * Spirometry FEV1 and FVC; * Hospital re-admission rates and mortality rates. The undertaking of a multidisciplinary-led programme of rehabilitation facilitates a better quality of life than a document-based rehabilitation programme in lung and or heart-lung transplant out-patients. The aim of the study is to construct an optimal programme of rehabilitation in lung or heart-lung patients.

Interventions

Sponsors

Royal Brompton & Harefield NHS Foundation Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients who have undergone either a lung or heart-lung transplant. * Fit for discharge from the Transplant Unit's Intensive Care Unit. * \> 18 years of age.

Exclusion criteria

* Patients under 18 years of age. * Patients unable to understand or comprehend the study.

Design outcomes

Primary

MeasureTime frame
Exercise Shuttle Test (metres completed)

Secondary

MeasureTime frame
Borg score
Quality of life: SF-36 and Chronic Respiratory Questionnaires
Spirometry
Hospital re-admission rates
Organ rejection

Countries

United Kingdom

Contacts

Primary ContactMICHAEL G PREEDY, BSc Econ
M.Preedy@rbh.nthames.nhs.uk02073528121
Backup ContactCHRISTOPHER THEAKER
C.Theaker@rbh.nthames.nhs.uk02073528121

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026